Roche Diabetes Drug Trial Met Primary End Points
A clinical trial showed enicepatide effectively reduced A1c levels and body weight in adults with type 2 diabetes.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you trust emerging weight-loss and diabetes drugs as safe long-term health solutions?
Roche announced that its experimental once-weekly treatment, enicepatide, successfully met primary end points in a 48-week phase 2 clinical trial. The study enrolled 447 adults living with type 2 diabetes and obesity to test the drug's efficacy and safety.
Why it matters
The positive results for enicepatide provide a potential new therapeutic option for the roughly 600 million adults globally who suffer from diabetes. By targeting both GLP-1 and GIP receptors, the drug aims to address both glycemic control and weight management in a single treatment.
In the phase 2 CT-388-104 trial, patients receiving the 24 mg dose achieved a 2.65% reduction in hemoglobin A1c and 15.5% mean weight loss. Only 2.0% of participants discontinued the study due to adverse events, which were primarily mild-to-moderate gastrointestinal effects.
The players
Roche
Roche is a global research-based healthcare company that develops pharmaceuticals and diagnostics.
The details
The trial utilized a multicenter, parallel-group design to evaluate subcutaneous enicepatide, a synthetic peptide that activates GLP-1 and GIP receptors while favoring cAMP signaling. The results establish a foundation for further investigation as the company moves toward later-stage development.
Timeline
The clinical trial treatment period lasted for 48 weeks.
Roche plans to initiate phase 3 glycemic control trials in the first half of 2027.
The Big Picture
This development follows a pattern of intense industry competition to expand the availability of dual-agonist weight loss and diabetes treatments within the GLP-1 and GIP receptor agonist therapeutic class.
While the drug is not yet approved for public use, these trial results indicate a future treatment path that could assist patients in managing both blood sugar levels and weight simultaneously. Individuals should consult their doctors for updates on medication availability and current standard-of-care options.
The takeaway
The successful trial results mark a significant step toward potential new treatments for complex metabolic conditions. Patients and healthcare providers should monitor future phase 3 results to better understand the long-term safety and efficacy of this synthetic peptide therapy.
What happens next
Roche has scheduled the initiation of both a phase 3 glycemic control program and cardiovascular outcomes trials for the first half of 2027.
Further reading
For more on the current landscape of metabolic disorder treatments, visit the Diabetes section.
Live Poll
Do you trust emerging weight-loss and diabetes drugs as safe long-term health solutions?
